Kindly provide antibiotics commonly used according to system wise and their dose and side effect
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
antibiotic stewardship empiric therapy guideline
Antibiotics Commonly Used by System — Dose and Side Effects
Doses below are typical adult doses for common indications (renal/hepatic adjustment and pediatric dosing differ). This is a general clinical reference, not a substitute for local antibiograms/guidelines.
1. Respiratory System (Sinusitis, Pharyngitis, CAP, COPD exacerbation)
| Antibiotic | Class | Typical Adult Dose | Key Side Effects |
|---|---|---|---|
| Amoxicillin (± clavulanate) | Aminopenicillin | 500-875 mg PO q8-12h | Diarrhea, rash, hypersensitivity/anaphylaxis, C. difficile colitis |
| Azithromycin | Macrolide | 500 mg PO day 1, then 250 mg OD x4 days | GI upset, QT prolongation, hepatotoxicity, ototoxicity (high dose) |
| Clarithromycin | Macrolide | 250-500 mg PO q12h | GI upset, metallic taste, QT prolongation, drug interactions (CYP3A4) |
| Doxycycline | Tetracycline | 100 mg PO q12h | Photosensitivity, esophagitis, GI upset, teeth discoloration (avoid in children/pregnancy) |
| Levofloxacin / Moxifloxacin | Fluoroquinolone | Levo 500-750 mg OD; Moxi 400 mg OD | Tendinopathy/tendon rupture, QT prolongation, CNS effects (dizziness, seizures), peripheral neuropathy |
| Ceftriaxone | 3rd-gen cephalosporin | 1-2 g IV/IM OD | Diarrhea, biliary sludging, rash, C. difficile colitis |
| Piperacillin-tazobactam | Penicillin/BLI | 3.375-4.5 g IV q6-8h | GI upset, rash, hypersensitivity, electrolyte disturbance |
2. ENT Infections (Otitis media, Tonsillitis, Sinusitis)
| Antibiotic | Dose | Side Effects |
|---|---|---|
| Amoxicillin-clavulanate | 875/125 mg PO q12h | Diarrhea (higher with clavulanate), rash |
| Penicillin V (for streptococcal pharyngitis) | 500 mg PO q6-12h x10 days | GI upset, hypersensitivity |
| Cefuroxime | 250-500 mg PO q12h | GI upset, rash, cross-reactivity in penicillin allergy |
| Clindamycin (penicillin-allergic) | 300-450 mg PO q6-8h | Diarrhea, high risk of C. difficile colitis, metallic taste |
3. Gastrointestinal System (H. pylori, Peritonitis, Traveler's diarrhea)
| Antibiotic | Dose | Side Effects |
|---|---|---|
| Metronidazole | 400-500 mg PO/IV q8h | Metallic taste, GI upset, peripheral neuropathy (prolonged use), disulfiram-like reaction with alcohol |
| Amoxicillin (H. pylori regimen) | 1 g PO q12h with PPI + clarithromycin | Diarrhea, rash |
| Clarithromycin (H. pylori) | 500 mg PO q12h | GI upset, QT prolongation |
| Ciprofloxacin | 500-750 mg PO / 400 mg IV q12h | Tendon rupture, QT prolongation, GI upset, CNS effects |
| Ceftriaxone + Metronidazole (peritonitis/intra-abdominal) | Ceftriaxone 1-2 g IV OD + Metronidazole 500 mg IV q8h | See above |
| Rifaximin (traveler's diarrhea) | 200 mg PO q8h | Minimal systemic absorption; headache, flatulence |
4. Urinary/Genitourinary System (UTI, Pyelonephritis, STIs)
| Antibiotic | Dose | Side Effects |
|---|---|---|
| Nitrofurantoin (uncomplicated cystitis) | 100 mg PO q12h x5 days | GI upset, pulmonary fibrosis (long-term), hemolysis in G6PD deficiency, avoid in renal impairment |
| Trimethoprim-sulfamethoxazole | 160/800 mg PO q12h | Rash (Stevens-Johnson syndrome rarely), hyperkalemia, bone marrow suppression, photosensitivity |
| Ciprofloxacin (pyelonephritis) | 500 mg PO q12h or 400 mg IV q12h | Tendon rupture, QT prolongation, CNS effects |
| Ceftriaxone (gonorrhea) | 500 mg-1 g IM single dose | Injection site pain, rash, biliary sludging |
| Azithromycin (chlamydia) | 1 g PO single dose | GI upset, QT prolongation |
| Doxycycline (chlamydia/PID) | 100 mg PO q12h x7 days | Photosensitivity, esophagitis |
| Gentamicin (severe pyelonephritis, adjunct) | 5-7 mg/kg IV OD (levels monitored) | Nephrotoxicity, ototoxicity (vestibular and cochlear) - per Katzung's Pharmacology and Harrison's Principles of Internal Medicine, gentamicin is among the most nephro- and ototoxic aminoglycosides |
5. Skin and Soft Tissue Infections (Cellulitis, Abscess, MRSA)
| Antibiotic | Dose | Side Effects |
|---|---|---|
| Cephalexin | 500 mg PO q6h | GI upset, rash |
| Dicloxacillin | 250-500 mg PO q6h | GI upset, hypersensitivity |
| Clindamycin | 300-450 mg PO q6-8h / 600-900 mg IV q8h | Diarrhea, C. difficile colitis, rash |
| Trimethoprim-sulfamethoxazole (MRSA) | 1-2 DS tabs PO q12h | Rash, hyperkalemia, marrow suppression |
| Doxycycline (MRSA, outpatient, oral option for noncompliant patients) | 100 mg PO q12h | Photosensitivity, GI upset |
| Vancomycin (severe/MRSA, inpatient) | 15-20 mg/kg IV q8-12h (trough-guided) | Nephrotoxicity, "red man syndrome" (infusion reaction), ototoxicity |
| Piperacillin-tazobactam (necrotizing/polymicrobial) | 3.375-4.5 g IV q6-8h | GI upset, rash |
6. Central Nervous System (Bacterial Meningitis, Brain Abscess)
| Antibiotic | Dose | Side Effects |
|---|---|---|
| Ceftriaxone | 2 g IV q12h | Biliary sludging, rash, diarrhea |
| Vancomycin (added for resistant pneumococcus) | 15-20 mg/kg IV q8-12h | Nephrotoxicity, red man syndrome |
| Ampicillin (Listeria coverage, elderly/immunocompromised) | 2 g IV q4h | Rash, GI upset, seizures at high doses in renal failure |
| Metronidazole (anaerobic brain abscess) | 500 mg IV q8h | Peripheral neuropathy, metallic taste |
7. Bone and Joint (Osteomyelitis, Septic Arthritis)
| Antibiotic | Dose | Side Effects |
|---|---|---|
| Nafcillin/Oxacillin (MSSA) | 1-2 g IV q4-6h | Phlebitis, hepatotoxicity, interstitial nephritis |
| Vancomycin (MRSA) | 15-20 mg/kg IV q8-12h | Nephrotoxicity, red man syndrome |
| Ciprofloxacin + Rifampin (chronic/prosthetic) | Cipro 750 mg PO q12h; Rifampin 300-450 mg PO q12h | Tendon rupture; rifampin causes orange body secretions, hepatotoxicity, drug interactions |
8. Systemic/Sepsis (Broad-spectrum empirical)
| Antibiotic | Dose | Side Effects |
|---|---|---|
| Piperacillin-tazobactam | 4.5 g IV q6-8h | GI upset, rash, electrolyte disturbance |
| Meropenem | 1 g IV q8h | Seizures (especially with renal impairment/high dose), GI upset, rash |
| Vancomycin | 15-20 mg/kg IV q8-12h | Nephrotoxicity, red man syndrome, ototoxicity |
| Gentamicin/Amikacin (synergy, gram-negative) | Gentamicin 5-7 mg/kg IV OD | Nephrotoxicity, ototoxicity (both vestibular and cochlear, often irreversible) |
9. Ophthalmic (Conjunctivitis, Keratitis)
| Antibiotic | Dose | Side Effects |
|---|---|---|
| Ciprofloxacin/Moxifloxacin eye drops | 1-2 drops q2-4h (severe) or q6h | Local burning/stinging, rarely systemic absorption effects |
| Erythromycin ophthalmic ointment | Applied q6-8h | Local irritation, blurred vision |
Class-wise Summary of Major Side Effects
- Penicillins/Cephalosporins (beta-lactams): Hypersensitivity/anaphylaxis, rash, GI upset, C. difficile-associated diarrhea; cross-reactivity risk between penicillins and cephalosporins (low but present).
- Macrolides: GI upset, QT prolongation/torsades, hepatotoxicity, CYP3A4 drug interactions.
- Fluoroquinolones: Tendinopathy and tendon rupture (higher risk in elderly, steroid users), QT prolongation, CNS effects (seizures, confusion), peripheral neuropathy, aortic aneurysm risk (boxed warning).
- Aminoglycosides (gentamicin, amikacin, tobramycin): Nephrotoxicity and ototoxicity (vestibular and/or cochlear, often irreversible) - gentamicin and neomycin/tobramycin are the most nephro- and ototoxic agents in this class (Katzung's Basic and Clinical Pharmacology, 16th ed.).
- Tetracyclines: Photosensitivity, esophageal irritation, teeth discoloration and bone growth inhibition (avoid in pregnancy and children under 8).
- Sulfonamides (TMP-SMX): Rash including Stevens-Johnson syndrome, hyperkalemia, bone marrow suppression, hemolysis in G6PD deficiency.
- Vancomycin: Nephrotoxicity, red man syndrome (rate-related, not true allergy), ototoxicity at high levels.
- Metronidazole: Metallic taste, peripheral neuropathy with prolonged use, disulfiram-like reaction with alcohol.
- Clindamycin: High relative risk of C. difficile-associated diarrhea/colitis.
Note on Evidence
A targeted PubMed check for recent (2-year) systematic reviews/meta-analyses on antibiotic stewardship did not surface any findings that contradict standard system-wise empirical regimens above; results were focused on stewardship program implementation rather than dosing changes. Always confirm doses against your local antibiogram, renal/hepatic function, allergy history, and current national/institutional guidelines (e.g., IDSA, local formulary) before prescribing, since regimens and resistance patterns vary by region and evolve over time.
This is a shared conversation. Sign in to Orris to start your own chat.